BioSpace News Archive

Invictus Sterilization LLC., a Hickory, NC based provider of Hospital-Grade UV-C based surface and air sterilization products, announced today that the U.S. Food and Drug Administration (FDA) cleared its Aura Storm as a Class II ultraviolet medical air purifier.

Globally first dual immune checkpoint inhibitor bi-specific antibody approved for marketing.

Bayer AG announced today the opening of its new Research and Innovation Center at Kendall Square in Boston-Cambridge, Massachusetts (U.S.A.), expanding the company’s footprint into one of the world’s most innovative pharmaceutical research and development locations.

ALR Technologies SG Pte. Ltd (“ALRT” or the “Company”) (OTCQB: ALRT), the diabetes management company, announces the completion of a definitive manufacturing agreement with Infinovo Medical Co. Ltd (“Infinovo”) to manufacture and supply the Continuous Glucose Monitor (“CGM”) hardware that will be utilized as part of the ALRT GluCurve Pet CGM (the “Manufacturing Agreement”).

SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that it has successfully completed the development of its top-tier drug candidate SCI-110 to be used in its upcoming multinational, multicenter, Phase IIb study for Tourette Syndrome (“TS”).

Jaguar Health Enters Exclusive Crofelemer License and Commercialization Agreement with SynWorld Technologies for Canalevia for Treatment of Diarrhea in Dogs in China

Anitoa Systems, market leader in fast, portable molecular testing, today announced the availability of a CE-marked turn-key PCR solution for testing Monkeypox.

Newly Issued Patent Broadens Medical Uses of Oral APX3330 Therapy in Patients with Diabetes and Extends Expiry Thru 2038.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced findings from an analysis of post-marketing safety data evaluating RADICAVA® (edaravone) in a real-world setting during the first three years of availability in the United States (U.S.) for the treatment of amyotrophic lateral sclerosis (ALS).

NeuraLace Medical, (www.neuralacemedical.com), the developer and manufacturer of the Axon® Therapy device, is pleased to announce that the American Medical Association (AMA) has approved new Current Procedural Terminology (CPT) codes for Transcutaneous Magnetic Nerve Stimulation, a therapy which can help clinicians to treat patients with chronic neuropathic pain.